Duobrii in Combination With Biologics

Description

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Conditions

Psoriasis

Talk to us

Study Overview

On this page

Study Details

Study overview

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.

Duobrii in Combination With Biologics

Condition
Psoriasis
Intervention / Treatment

-

Contacts and Locations

East Windsor

Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States, 08520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female adult ≥ 18 years of age;
  • 2. Diagnosis of chronic plaque-type
  • 3. Psoriasis affecting 2%-10% BSA
  • 4. Patient is being treated with biologic therapy for a minimum of 24 weeks
  • 5. Able and willing to give written informed consent prior to performance of any study-related procedures
  • 1. Psoriasis affecting ˂2% or \>10% BSA
  • 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
  • 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
  • 4. Has previously used DUOBRII

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Psoriasis Treatment Center of Central New Jersey,

Study Record Dates

2020-09-01